📇 Rhumatologue · TROYES · (10) · Libéral

M JEAN-CLAUDE KARP

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
79.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 TROYES (10)LibéralRPPS 10001689842

4 publications sur 5 ans

📊 Reconnaissance scientifique : 5/100📝 20 articles publiés🇫🇷 Publications académiques françaises (2)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Towards an arthritis flare-responsive drug delivery system

Nature communications · 2018

📚 174 citations🎯 RCR 8.00Top 4% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractLocal delivery of therapeutics for the treatment of inflammatory arthritis (IA) is limited by short intra-articular half-lives. Since IA severity often fluctuates over time, a local drug delivery method that titrates drug release to arthritis activity would represent an attractive paradigm in IA therapy. Here we report the development of a hydrogel platform that exhibits disassembly and drug release controlled by the concentration of enzymes expressed during arthritis flares. In vitro, hydrogel loaded with triamcinolone acetonide (TA) releases drug on-demand upon exposure to enzymes or synovial fluid from patients with rheumatoid arthritis. In arthritic mice, hydrogel loaded with a fluorescent dye demonstrates flare-dependent disassembly measured as loss of fluorescence. Moreover, a single dose of TA-loaded hydrogel but not the equivalent dose of locally injected free TA reduces arthritis activity in the injected paw. Together, our data suggest flare-responsive hydrogel as a promising next-generation drug delivery approach for the treatment of IA.

Long-term changes in bone mineral density following total knee replacement

Clinical orthopaedics and related research · 1995

📚 63 citations🎯 RCR 3.49Top 13% NIH🩺 Clinique

On-demand drug delivery from self-assembled nanofibrous gels: a new approach for treatment of proteolytic disease

Journal of biomedical materials research. Part A · 2011

📚 37 citations🎯 RCR 1.27

Lire l'abstract Crossref ↓

AbstractLocal delivery of drugs offers the potential for high local drug concentration while minimizing systemic toxicity, which is often observed with oral dosing. However, local depots are typically administered less frequently and include an initial burst followed by a continuous release. To maximize efficiency of therapy, it is critical to ensure that drug is only released when needed. One of the hallmarks of rheumatoid arthritis, for example, is its variable disease activity consisting of exacerbations of inflammation punctuated by periods of remission. This presents significant challenges for matching localized drug delivery with disease activity. An optimal system would be nontoxic and only release drugs during the period of exacerbation, self‐titrating in response to the level of inflammation. We report the development of an injectable self‐assembled nanofibrous hydrogel, from a generally recognized as safe material, which is capable of encapsulation and release of agents in response to specific enzymes that are significantly upregulated in a diseased state including matrix metalloproteinases (MMP‐2 and MMP‐9) and esterases. We show that these self‐assembled nanofibrous gels can withstand shear forces that may be experienced in dynamic environments such as joints, can remain stable following injection into healthy joints of mice, and can disassemble in vitro to release encapsulated agents in response to synovial fluid from arthritic patients. This novel approach represents a next‐generation therapeutic strategy for localized treatment of proteolytic diseases. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

Cookies & analyse de trafic

M JEAN-CLAUDE KARP

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (2)

Top publications · les plus citées

Publications scientifiques (26) — classées par pathologie

Transversal17

Santé mentale / fatigue4

Gériatrie2

Lombalgie2

Arthrose1

Essai clinique1

Lupus1

Qualité de vie / PROMs1

Revue générale1

Sjögren1

Partager cette fiche